82 results
Page 2 of 5
POS AM
gy3yqq5tcr5ur
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm
POS AM
6rl6h1a
4 Aug 23
Prospectus update (post-effective amendment)
4:05pm
6-K
EX-99.1
9zw2gl1dp53aw
6 Jun 23
XORTX Announces PKD Presentation
7:00am
6-K
EX-99.2
eypretc guflweh52m
16 May 23
Condensed Interim Consolidated Financial Statements
9:32am
6-K
EX-99.1
35jrteehud 0dl
4 May 23
FDA Confirms Eligibility of XORLOâ„¢ for Accelerated Approval
7:00am
6-K
EX-99.3
jqxag00x
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.2
9f4afcpo8
3 Apr 23
Consolidated Financial Statements
6:05am
6-K
EX-99.1
ifbi1y d4nv
19 Dec 22
XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study
8:12am
6-K
EX-99.1
of1bu
28 Nov 22
XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study
7:00am
424B3
o1oh78j6n gj
14 Nov 22
Prospectus supplement
1:51pm
6-K
EX-99.2
145jwt a8
14 Nov 22
Condensed Interim Consolidated Financial Statements
1:04pm
6-K
EX-99.1
4g95tf6
26 Oct 22
XORTX Receives Further No Objection Letter from Health Canada
7:52am
6-K
EX-99.1
jt4 pqh9m6
6 Oct 22
A.G.P./Alliance Global Partners
4:47pm
424B4
l1t7tgzv91h nk
5 Oct 22
Prospectus supplement with pricing info
5:24pm
POS AM
8hivc33ios bzvku1m6
29 Sep 22
Prospectus update (post-effective amendment)
9:49pm
F-1/A
3dl9cm9ppsrmqnj24m4
21 Sep 22
Registration statement (foreign) (amended)
4:20pm
6-K
EX-99.1
s3i3bj
19 Sep 22
XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration
7:00am